Your session is about to expire
← Back to Search
A arm (DA-90) for Acute Myeloid Leukemia (PALG-AML1/2016 Trial)
PALG-AML1/2016 Trial Summary
This trial will study two different induction chemotherapy regimens for newly diagnosed AML patients to see which is more effective. Bone marrow aspiration with MRD will be performed on day seven after induction to evaluate response to treatment. Patients who do not achieve complete remission (CR) after two induction courses will be randomized to one of two standard salvage regimens.
- Acute Myeloid Leukemia
PALG-AML1/2016 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPALG-AML1/2016 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PALG-AML1/2016 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this study enrolling new participants at this time?
"According to the clinicaltrials.gov website, this study is still looking for volunteers. The trial was originally posted on July 3rd, 2017 and the listing was last updated on September 30th, 2021."
Has the FDA cleared arm A (DA-90) for use?
"There is both efficacy and safety data from prior clinical trials to support A arm (DA-90), which is why it was given a safety score of 3."
Will this study consider patients who are middle-aged or older?
"This clinical trial only allows patients aged 18 to 60 to enroll. Out of the 2,132 trials on this website, only 452 are for people under the age of 18 and 1,280 are for patients over the age of 65."
What is the most common reason why doctors prescribe arm A (DA-90)?
"The most popular treatment for myeloblastic leukemia is A arm (DA-90). A arm (DA-90) is also able to help patients with neoplasms, leptomeningeal metastases, and chronic lymphocytic leukemia (cll)."
Which patients does this research project seek to enroll?
"This medical trial is looking for 582 individuals between the ages of 18 and 60 who have leukemia, myeloid, acute. In addition to meeting these general requirements, patients must also meet the following specific criteria: Be previously untreated for AML, have AML de novo, have AML secondary to myelodysplastic syndromes (MDS), be of age ≥ 18 years and ≤60 years while signing a written consent form, have a general state according to the ECOG ≤ 2 scale (Annex 1), have an index of comorbidities, have HCT-CI ≤ 3, according to"
Are there similar trials that have used DA-90 before?
"There are 752 clinical trials currently underway that involve the A arm (DA-90). Of these, 108 are in Phase 3. The A arm (DA-90) trials are being conducted in Saint Louis, Missouri, but there are a total of 18268 locations where these trials are taking place."
Share this study with friends
Copy Link
Messenger